Ascletis Pharma scraps liver disease program; Another reverse merger

Plus, news about BenevolentAI, Adaptive Biotechnologies, Eisai, CNX Therapeutics, Vanda Pharmaceuticals and Nucleai:

Ascletis Pharma ends liver disease program: The Chinese biotech will not pursue further development of ASC42 for primary biliary cholangitis after Phase 2 data suggested a lack of competitiveness versus competing candidates. Ascletis also dropped clinical work on the FXR agonist in hepatitis B. — Ayisha Sharma

Kintara inks reverse merger with TuHURA: The combined company will go by TuHURA Biosciences and change its ticker from $KTRA to $HURA. TuHURA’s personalized cancer vaccine is in Phase 3. It has bifunctional ADCs, as well. The deal marks the third biotech reverse merger this week, following the creation of Traws Pharma and Oruka Therapeutics. — Kyle LaHucik

BenevolentAI founder…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks